Earnings due 11 Mar 2026 pre-market: PPGN.SW PolyPeptide AG (SIX) guidance key

We enter pre-market trading with PolyPeptide Group AG (PPGN.SW) at the centre of an earnings spotlight. The company reports after markets on 12 Mar 2026, and investors will parse revenue, margins and guidance for peptide CDMO demand. The stock trades at CHF 25.10 with a +2.66% move today and volume 67700.00. We summarise what the report can mean for PPGN.SW stock, valuation and near-term trading in Switzerland (SIX)

Earnings outlook and schedule for PPGN.SW stock

PolyPeptide Group AG reports results on 12 Mar 2026 after market close in the US time zone, which is early pre-market sensitivity in Switzerland. The market currently prices PPGN.SW stock at CHF 25.10 with a one‑day change of +0.65. Analysts will watch top-line growth and any change to contract pipeline commentary.

Key items to watch in the PPGN.SW stock earnings report

We expect focus on contract wins, clinical supply ramp and margin mix for proprietary and generics work. Watch revenue per share trends and free cash flow, since operating cash flow per share is 4.18 and free cash flow per share is 0.98. Management commentary on capacity utilisation and neoantigen programmes could move the stock.

PPGN.SW stock valuation and financials

PolyPeptide shows mixed fundamentals: EPS is -0.94 and trailing PE reads -26.70, while price to sales is 2.48 and price to book is 2.78. Market cap stands at CHF 828085370.00 with shares outstanding 32991449.00. The company has a current ratio of 1.62 and debt to equity 0.30, which support liquidity despite negative net income.

PPGN.SW stock technicals and trading setup

Technically, the 50‑day average is CHF 26.92 and the 200‑day average is CHF 24.61. RSI sits near 45.56, showing neutral momentum. Bollinger mid is 25.55, which is close to the current price and suggests limited intraday volatility. Traders should note the relative volume of 1.08 ahead of the release.

Meyka grade and analyst context for PPGN.SW stock

Meyka AI rates PPGN.SW with a score out of 100: 70.52/100 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating from other models shows shortfalls on profitability, but Meyka’s score balances cash flow strength and growth pipeline. These grades are not guaranteed and we are not financial advisors.

Risks and opportunities for PPGN.SW stock

Upside drivers include larger contract awards, improved margin mix, and faster neoantigen ramp. Key risks are continued negative EPS, working capital swings, and slower generic demand. Sector context matters: Healthcare peers have average P/E near 30.19 and stronger net margins, so PolyPeptide must show operational leverage to trade in line with the sector.

Final Thoughts

Short term, PPGN.SW stock is an earnings event trade ahead of the 12 Mar 2026 release. The market price is CHF 25.10 and intraday action shows modest buying with volume 67700.00. For investors we provide scenario targets: a conservative price target CHF 28.00 (+11.55%), a base case CHF 32.00 (+27.49%), and a bull case CHF 36.00 (+43.43%). Meyka AI’s forecast model projects a yearly price of CHF 32.87, implying +30.96% from today’s price. Forecasts are model‑based projections and not guarantees. We expect guidance, margin commentary and cash flow clarity to be the immediate drivers for PPGN.SW stock in the SIX market in Switzerland. For the full company site and filings see the PolyPeptide website and our stock page for live updates company site and PPGN.SW stock page. Meyka AI is an AI‑powered market analysis platform delivering real‑time insights

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.